highly significantp = 0.025
Despite no significant OS advantage at 34 months, there was a highly significant EFS advantage in the high dose arm (53% vs 10%, p = 0.025).
Despite no significant OS advantage at 34 months, there was a highly significant EFS advantage in the high dose arm (53% vs 10%, p = 0.025).